Doctor talking with patient

IBM Watson™ Genomics from Quest Diagnostics®

The path to more targeted cancer treatment options starts with KNOWING

Test Code 93234

Today more patients are benefitting from personalized treatments that target cancer cells containing specific genetic mutations. However, it can be difficult to decide which targeted therapies are most appropriate, as it requires a time-consuming analysis of massive amounts of data. Watson Genomics from Quest Diagnostics accelerates this analysis and provides personalized therapeutic options for your patient's unique situation. With this enhanced insight, you can take more informed actions for treatment and feel more certain about the best path forward.

Watson Genomics from Quest Diagnostics combines Quest’s state-of-the-art tumor analysis with the cognitive computing of IBM’s Watson and the deep cancer treatment expertise of Memorial Sloan Kettering Cancer Center (MSK). The Broad Institute of MIT and Harvard is providing additional genome sequencing capabilities as part of the collaboration.

From analysis to action steps

Quest Diagnostics sequences and analyzes the tumor’s genomic makeup to help oncologists understand the unique cancer-causing mutations specific to that individual patient’s sample. Watson then compares those mutations against relevant medical literature, clinical studies, pharmacopeia and carefully annotated rules created by leading oncologists.

A Quest Diagnostics pathologist will review and validate the results and prepare a report that delivers insight into personalized, targeted treatment options, including alternate therapies and clinical trials that may be appropriate for your patient.

Delivering greater cancer insight

The test identifies base pair substitutions, insertions and deletions in hotspots in 34 genes. Quest plans to launch two broader panels in 2017, providing the option to analyze up to 400 genes and additional copy number alterations and gene arrangements for even more comprehensive insight into your patient’s unique profile.

The path to more targeted cancer treatment starts today